LabCorp Clinical Trials Selected as a Preferred Provider for Global Central Laboratory Services by Bristol-Myers Squibb

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2013 to September 11, 2013 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp Announces Change to Board of Directors

Adam H. Schechter Named to the Board of Directors Effective April 1, 2013 BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Adam H. Schechter , Executive Vice President and President, Global Human Health ,

LabCorp is Scheduled to Present at the Barclays Capital 2013 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 6, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2013 Global Healthcare Conference in Miami Beach, FL.

LabCorp Launches Next Generation Sequencing Assay for Familial Cardiac Disease

New technology compliments disease focused approach to diagnostic testing BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 25, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it has launched its clinical next generation sequencing assay, GeneSeq®: Cardio for

Laboratory Corporation of America® Holdings Announces 2012 Fourth Quarter and Full Year Results

Q4 Diluted EPS of $1.26 Q4 Adjusted EPS Excluding Amortization of $1.54 , Reduced by a $0.09 Impact from Inclement Weather 2012 Diluted EPS of $5.99 2012 Adjusted EPS Excluding Amortization of $6.82 , an Increase of 7.1% Board Authorizes New $1 Billion Share Repurchase Program BURLINGTON, N.C.

LabCorp Biorepository Receives Industry Accreditation from College of American Pathologists

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 9, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the recent accreditation of its Biorepository by the College of American Pathologists (CAP). CAP’s inaugural accreditation program was developed to establish

LabCorp is Scheduled to Present at the 31st Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the 31 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

Laboratory Corporation of America® Holdings Announces 2012 Third Quarter Results

LabCorp Reports Q3 Diluted EPS of $1.53 and Adjusted EPS Excluding Amortization of $1.76 , up 9.3% BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 18, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced results for the quarter ended September 30, 2012 .